Company’s 36-month beta value is 2.41.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy”, 5 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for SLDB is 56.60M, and currently, short sellers hold a 14.27% ratio of that floaft. The average trading volume of SLDB on July 03, 2025 was 1.73M shares.
SLDB stock’s latest price update
Solid Biosciences Inc (NASDAQ: SLDB)’s stock price has increased by 3.23% compared to its previous closing price of $4.87. However, the company has seen a 4.52% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-01 that CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 105,330 restricted stock units (“RSUs”) to seven newly hired employees.
SLDB’s Market Performance
Solid Biosciences Inc (SLDB) has seen a 4.52% rise in stock performance for the week, with a 43.64% gain in the past month and a 36.25% surge in the past quarter. The volatility ratio for the week is 9.40%, and the volatility levels for the past 30 days are at 10.01% for SLDB. The simple moving average for the last 20 days is 6.95% for SLDB stock, with a simple moving average of 8.81% for the last 200 days.
Analysts’ Opinion of SLDB
Many brokerage firms have already submitted their reports for SLDB stocks, with Citigroup repeating the rating for SLDB by listing it as a “Buy”. The predicted price for SLDB in the upcoming period, according to Citigroup is $14 based on the research report published on June 26, 2025 of the current year 2025.
Truist, on the other hand, stated in their research note that they expect to see SLDB reach a price target of $16. The rating they have provided for SLDB stocks is “Buy” according to the report published on January 08th, 2025.
JMP Securities gave a rating of “Mkt Outperform” to SLDB, setting the target price at $15 in the report published on December 10th of the previous year.
SLDB Trading at 32.76% from the 50-Day Moving Average
After a stumble in the market that brought SLDB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.52% of loss for the given period.
Volatility was left at 10.01%, however, over the last 30 days, the volatility rate increased by 9.40%, as shares surge +32.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +47.96% upper at present.
During the last 5 trading sessions, SLDB rose by +5.51%, which changed the moving average for the period of 200-days by -36.00% in comparison to the 20-day moving average, which settled at $4.70. In addition, Solid Biosciences Inc saw -19.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SLDB starting from Kahn Clare, who purchase 1,860 shares at the price of $5.34 back on Mar 11 ’25. After this action, Kahn Clare now owns 2,960 shares of Solid Biosciences Inc, valued at $9,924 using the latest closing price.
Bain Capital Life Sciences Inv, the 10% Owner of Solid Biosciences Inc, purchase 1,000,000 shares at $4.03 during a trade that took place back on Feb 19 ’25, which means that Bain Capital Life Sciences Inv is holding 5,034,582 shares at $4,030,000 based on the most recent closing price.
Stock Fundamentals for SLDB
The total capital return value is set at -0.45%. Equity return is now at value -55.30%, with -47.14% for asset returns.
Based on Solid Biosciences Inc (SLDB), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -4.51. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -807.45.
Currently, EBITDA for the company is -121.9 million with net debt to EBITDA at 1.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.89.
Conclusion
In a nutshell, Solid Biosciences Inc (SLDB) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
